The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...